A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors

[1]  S. Kondo,et al.  Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line. , 2001, Cancer letters.

[2]  H. Ashino,et al.  Inhibition of angiogenesis by humulone, a bitter acid from beer hop. , 2001, Biochemical and biophysical research communications.

[3]  R. Brekken,et al.  Vascular endothelial growth factor and vascular targeting of solid tumors. , 2001, Anticancer research.

[4]  T. Suda,et al.  Role for Angiogenesis Expression of Angiopoietin-2 in Human Glioma Cells and Its Updated Version , 2001 .

[5]  S. Hibino,et al.  Anti-angiogenic activity of a novel synthetic agent, 9alpha-fluoromedroxyprogesterone acetate. , 1999, Cancer letters.

[6]  A. Hartmann,et al.  Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. , 1999, Cancer research.

[7]  D A Bloch,et al.  Tissue oxygen distribution in head and neck cancer patients , 1999, Head & neck.

[8]  M. Shimamura,et al.  Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. , 1996, European journal of pharmacology.

[9]  K. Hillan,et al.  Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. , 1996, Cancer research.

[10]  P. Workman,et al.  The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. , 1995, British Journal of Cancer.

[11]  M. Matsumoto,et al.  Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Moriya,et al.  Quantitative RT-PCR assay detecting the transcriptional induction of vascular endothelial growth factor under hypoxia. , 1994, Biochemical and biophysical research communications.

[13]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[14]  Y. Shibamoto,et al.  KIH-802: 2-nitroimidazole-1-acetohydroxamate as a hypoxic cell radiosensitizer. , 1989, International journal of radiation oncology, biology, physics.

[15]  I. Stratford,et al.  The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. , 1989, International journal of radiation oncology, biology, physics.

[16]  A. Cockett,et al.  Efficacy of antitumor chemotherapy in C3H mice enhanced by the antiangiogenesis steroid, cortisone acetate. , 1987, Cancer research.

[17]  P. Workman,et al.  Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. , 1987, Biochemical pharmacology.

[18]  C. J. Koch,et al.  A novel technique for measuring human tissue pO2 at the cellular level. , 1986, British Journal of Cancer.

[19]  S. Rockwell,et al.  Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. , 1984, International journal of radiation oncology, biology, physics.

[20]  J. Brown,et al.  Role of glutathione in the hypoxic cell cytotoxicity of misonidazole. , 1983, Cancer research.

[21]  D. M. Brown,et al.  SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. , 1981, International journal of radiation oncology, biology, physics.

[22]  A. J. Varghese,et al.  Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole. , 1980, Cancer research.

[23]  J. Brown,et al.  Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro 7-0582. , 1975, Radiation research.

[24]  J. Fowler,et al.  Radiosensitization of C3H Mouse Mammary Tumours by a 2-Nitroimidazole Drug , 1974, British Journal of Cancer.

[25]  P. Grigsby,et al.  Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation Therapy Oncology Group. , 1999, International journal of radiation oncology, biology, physics.

[26]  P. Wen,et al.  Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. , 1998, International journal of radiation oncology, biology, physics.

[27]  W. Bloomer,et al.  9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. , 1996, Oncology research.

[28]  B. Ebert,et al.  Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. , 1995, The American journal of physiology.

[29]  D. Ruiter,et al.  Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. , 1995, The American journal of pathology.

[30]  J. Caro,et al.  Hypoxia regulatory elements of the human vascular endothelial growth factor gene. , 1994, Cellular & molecular biology research.

[31]  H. Nagasawa,et al.  Radiosensitizing, toxicological, and pharmacokinetic properties of hydroxamate analogues of nitroimidazoles as bifunctional radiosensitizers/chemical modifiers. , 1992, International journal of radiation oncology, biology, physics.

[32]  E. Clarke,et al.  Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. , 1979, International journal of radiation biology and related studies in physics, chemistry, and medicine.